Journal carpathia16's Journal: GW Pharmaceuticals' CEO talks Epidiolex, future of cannabidiol medicine
This is a make-or-break spring for GW Pharmaceuticals and its billion-dollar investment in a cannabidiol-based drug. The London-based firm aims to develop the first FDA-approved medicine from plant-derived cannabis compounds. The U.S. Food and Drug Administration could decide as early Read More http://bit.ly/2HKayil
GW Pharmaceuticals' CEO talks Epidiolex, future of cannabidiol medicine More Login
GW Pharmaceuticals' CEO talks Epidiolex, future of cannabidiol medicine
Slashdot Top Deals